Executive readout · one minute
What the filings say
- 8-K earnings release · filed Oct 29, 2026
- CareDx reported third-quarter revenue of $139 million, up 39% year-over-year, and Adjusted EBITDA of $30 million. It raised 2026 revenue guidance to $520 million to $530 million and Adjusted EBITDA guidance to $90 million to $100 million.
- 10-Q report · filed Oct 29, 2026
- CareDx reported $139 million revenue and $19 million net income for the three months ended September 30, 2026. It sold its lab products business to Eurobio for $171.7 million and acquired Naveris for $203.3 million.
The audio replay and transcript follow the call.